FUNDC1

FUN14 domain-containing protein 1 · Q8IVP5 · FUNDC1 on Sugi Atlas →

1,246 patent compounds predicted against FUNDC1, 1,083 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Oleanolic_Acid (SCHEMBL71070)	1.00	2/20
Oleanolic_Acid (SCHEMBL741472)	1.00	2/20
Oleanolic_Acid (SCHEMBL741473)	1.00	2/20
Oleanolic_Acid (SCHEMBL1876845)	1.00	2/20
Oleanolic_Acid (SCHEMBL7739312)	1.00	2/20
Oleanolic_Acid (SCHEMBL12313106)	1.00	2/20
Oleanolic_Acid (SCHEMBL12337275)	1.00	2/20
Oleanolic_Acid (SCHEMBL13395360)	1.00	2/20
Oleanolic_Acid (SCHEMBL13425080)	1.00	2/20
Oleanolic_Acid (SCHEMBL13455967)	1.00	2/20
Oleanolic_Acid (SCHEMBL15382987)	1.00	2/20
Oleanolic_Acid (SCHEMBL15714063)	1.00	2/20
Oleanolic_Acid (SCHEMBL16126185)	1.00	2/20
Oleanolic_Acid (SCHEMBL16153016)	1.00	2/20
Oleanolic_Acid (SCHEMBL16999276)	1.00	2/20
Oleanolic_Acid (SCHEMBL18420569)	1.00	2/20
Oleanolic_Acid (SCHEMBL18688342)	1.00	2/20
Oleanolic_Acid (SCHEMBL18688362)	1.00	2/20
Oleanolic_Acid (SCHEMBL9997853)	0.98	2/20
Oleanolic_Acid (SCHEMBL13728119)	0.96	2/20

Clinical trials — most relevant to FUNDC1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients	PHASE4	UNKNOWN
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease	PHASE3	RECRUITING
Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy	PHASE3	RECRUITING
Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome	PHASE2	RECRUITING
A Clinical Study to Evaluate the Safety of MF1, a New Treatment for Parkinson's Disease-related Disorders (MF1 Study)	PHASE1	RECRUITING
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)	EARLY_PHASE1	COMPLETED
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction	EARLY_PHASE1	RECRUITING
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise	nan	COMPLETED
mTORC1 and Autophagy in Human Brown Adipocytes	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Skeletal Muscle Regeneration in Survivors of Critical Illness: How to Prevent Satellite Cell Failure?	nan	RECRUITING
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants	nan	RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
ACTIV- Exercise Intervention in Healthy Young Men	nan	COMPLETED
Mitoquines in COPD	nan	UNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
GDF-15 as a Biomarker for Mitochondrial Disease	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Ultrastructural Characteristics of Mitochondria in Cardiomyocytes in Heart Failure	nan	RECRUITING
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Mitochondrial DNA in Peripheral Blood Leukocytes	nan	NOT_YET_RECRUITING
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
Nicotinamide Riboside and Mitochondrial Biogenesis	nan	COMPLETED
Establishment of Biomarkers for Fabry Disease	nan	COMPLETED
Paediatric Obesity and Cardiovascular Dysfunction	nan	COMPLETED
Effects of Acute Energy Deficit and Aerobic Exercise on Muscle Quality	nan	COMPLETED
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease	nan	UNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Pathogenic Insights and Search for Biomarkers in RFC1-ataxia/CANVAS	nan	RECRUITING
Autophagy Bladder Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a FUNDC1 binder may also engage these)

Protein	Name	Similarity
Q5BJS4	—	1.000	Q5BJS4 →
Q9DB70	—	1.000	Q9DB70 →
F1N5S9	—	1.000	F1N5S9 →
E1BWM5	—	0.995	E1BWM5 →
B1H3B1	—	0.985	B1H3B1 →
Q58EA0	—	0.982	Q58EA0 →
Q6DH87	—	0.968	Q6DH87 →
Q4RY26	—	0.967	Q4RY26 →
Q9D6K8	—	0.938	Q9D6K8 →
Q6GM44	—	0.930	Q6GM44 →
Q6P4H8	—	0.930	Q6P4H8 →
Q99KU0	—	0.927	Q99KU0 →
Q5R9I4	—	0.927	Q5R9I4 →
Q0VCK9	—	0.927	Q0VCK9 →
Q5R9K4	—	0.927	Q5R9K4 →
GHITM	Growth hormone-inducible transmembrane protein	0.927	landscape →
Q08DM5	—	0.926	Q08DM5 →
Q91ZQ0	—	0.925	Q91ZQ0 →
VMP1	Vacuole membrane protein 1	0.924	landscape →
Q9NYZ1	—	0.924	Q9NYZ1 →
D3ZXD8	—	0.922	D3ZXD8 →
B1AZA5	—	0.922	B1AZA5 →
Q6NYY9	—	0.922	Q6NYY9 →
Q9D7J4	—	0.921	Q9D7J4 →
Q9H330	—	0.921	Q9H330 →
Q3ZBL5	—	0.920	Q3ZBL5 →
Q9D8T4	—	0.920	Q9D8T4 →
Q9CPQ3	—	0.920	Q9CPQ3 →
Q75Q41	—	0.919	Q75Q41 →
Q29S14	—	0.919	Q29S14 →